AI Buyer Insights:

Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

Michelin, an e2open customer evaluated Oracle Transportation Management

Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

Westpac NZ, an Infosys Finacle customer evaluated nCino Bank OS

Swedbank, a Temenos T24 customer evaluated Oracle Flexcube

Cantor Fitzgerald, a Kyriba Treasury customer evaluated GTreasury

Wayfair, a Korber HighJump WMS customer just evaluated Manhattan WMS

Moog, an UKG AutoTime customer evaluated Workday Time and Attendance

Michelin, an e2open customer evaluated Oracle Transportation Management

Citigroup, a VestmarkONE customer evaluated BlackRock Aladdin Wealth

List of Genedata Biopharma Platform Customers

loading spinner icon



Apply Filters For Customers

Logo Customer Industry Empl. Revenue Country Vendor Application Category When SI Insight
Agenus Life Sciences 400 $161M United States Genedata Genedata Biopharma Platform Life Science R&D Platforms 2018 n/a
In 2018, Agenus implemented Genedata Biopharma Platform to consolidate antibody discovery workflows and support its immuno-oncology and vaccine R&D programs. The Genedata Biopharma Platform was deployed as an end-to-end Life Science R&D Platforms solution to standardize data capture and workflow management across research activities and to provide a single backbone for discovery-through-selection processes across the company. The implementation configured modules for screening, engineering, expression, purification, and analytics for large-molecule and antibody workflows, including support for bispecifics and next-generation molecule types. Molecule, sample, assay, and analytics data flows were instrumented to capture developability and manufacturability attributes alongside experimental results, aligning platform capabilities with antibody discovery and candidate progression processes. Genedata Biopharma Platform was integrated into Agenus’s broader data ecosystem, explicitly linking with the company’s Intelligent Re search AIR platform to enable shared access to large-molecule R&D data. Data and information were federated between project teams and research sites in the US and the UK, enabling cross-site collaboration and centralized access to assay and analytics outputs. Governance and operational workflows were restructured to use the Genedata Biopharma Platform as the authoritative source for therapeutic candidate evaluation, enabling systematic and transparent decision-making when selecting candidates for clinical progression. The platform augmented Agenus scientists’ ability to capture, process, and interpret complex biologics data and served as a core component of the company’s collaborative data and information platform.
Amgen Life Sciences 28000 $33.4B United States Genedata Genedata Biopharma Platform Life Science R&D Platforms 2018 n/a
In 2018 Amgen implemented Genedata Biopharma Platform to support a new workflow for development of bispecific antibody therapeutics, targeting high-throughput binding and large molecule assay analysis. The deployment centered on discovery scientists analyzing high-volume assay outputs to accelerate candidate selection, and it is positioned within the Life Science R&D Platforms category to support research informatics needs. The implementation relied on Genedata Screener as the analytic engine of the Genedata Biopharma Platform, applying automated analysis of high-volume data, automated fitting, and result derivation. Built-in business logic and pre-defined processing parameters were configured to standardize curve fitting, endpoint calculation, and result flagging, enabling repeatable, auditable processing of large molecule assay data. Operational integration included reliable reporting pipelines to Amgen's data warehouse and generation of reports containing key result values and raw data traces for downstream review. Governance and process change emphasized consistent analysis through parameterized workflows and automated result derivation, and the initiative explicitly enabled rapid identification of rare bispecific molecules with promising properties, consistent analysis across experiments, and easier sharing of results via warehouse reporting.
AstraZeneca Life Sciences 94300 $74.0B United Kingdom Genedata Genedata Biopharma Platform Life Science R&D Platforms 2019 n/a
In 2019, AstraZeneca deployed the Genedata Biopharma Platform to automate mass spectrometry based high throughput screening data processing for Discovery Sciences in Cambridge, UK. The Genedata Biopharma Platform was implemented as a Life Science R&D Platforms solution to support Acoustic Mist Ionization Mass Spectrometry AMI MS workflows and centralize MS data handling for mechanistic biology and profiling teams. Deployment centered on Genedata Expressionist as the primary processing module, configured with automated, customizable workflows that parse raw AMI MS files and assign spectra to individual wells from multi 384 well plate runs. Key capabilities implemented include dynamic peak detection and clustering algorithms, metadata driven automated processing, spectrum quality filtering, and configurable export pipelines, enabling single click processing of complex AMI MS data sets. Integration workstreams routed processed results into the existing Genedata Screener analysis platform, with each AMI MS file automatically uploaded and processed using predefined workflows before seamless export to Screener for plate wise visualization and QC. The implementation explicitly supports AMI MS instrument output and high throughput screening pipelines, processing example data sets of 150 times 384 well plates within an automated end to end flow. Governance was enforced through user definable settings and lockable workflows, enabling reproducible, auditable processing across laboratories and facilitating shared workflow templates for assay development. Detailed visualization and inspection at every processing stage were configured to support assay optimization, triage of false positives, and traceable data review practices. Measured outcomes reported by AstraZeneca include a seven fold decrease in processing time with elimination of potentially error inducing manual interactions, with a representative workflow reducing processing from approximately three hours to around 25 minutes for large plate sets. The solution preserved flexibility to handle data from any mass spectrometer and to accommodate multiple assay strategies, while improving consistency and traceability of HTS MS data.
Life Sciences 92815 $55.5B Germany Genedata Genedata Biopharma Platform Life Science R&D Platforms 2018 n/a
Life Sciences 34100 $48.3B United States Genedata Genedata Biopharma Platform Life Science R&D Platforms 2022 n/a
Life Sciences 60 $15M United Kingdom Genedata Genedata Biopharma Platform Life Science R&D Platforms 2018 n/a
Life Sciences 6000 $2.3B Switzerland Genedata Genedata Biopharma Platform Life Science R&D Platforms 2020 n/a
Life Sciences 2635 $2.3B Denmark Genedata Genedata Biopharma Platform Life Science R&D Platforms 2020 n/a
Life Sciences 150 $131M United States Genedata Genedata Biopharma Platform Life Science R&D Platforms 2020 n/a
Life Sciences 73000 $64.2B United States Genedata Genedata Biopharma Platform Life Science R&D Platforms 2019 n/a
Showing 1 to 10 of 16 entries

Buyer Intent: Companies Evaluating Genedata Biopharma Platform

ARTW Buyer Intent uncovers actionable customer signals, identifying software buyers actively evaluating Genedata Biopharma Platform. Gain ongoing access to real-time prospects and uncover hidden opportunities. Companies Actively Evaluating Genedata Biopharma Platform for Life Science R&D Platforms include:

  1. Shimadzu, a Japan based Healthcare organization with 14219 Employees
  2. Irusri Sweden, a Sweden based Professional Services company with 10 Employees
  3. University at Buffalo, a United States based Education organization with 6037 Employees

Discover Software Buyers actively Evaluating Enterprise Applications

Logo Company Industry Employees Revenue Country Evaluated
No data found
FAQ - APPS RUN THE WORLD Genedata Biopharma Platform Coverage

Genedata Biopharma Platform is a Life Science R&D Platforms solution from Genedata.

Companies worldwide use Genedata Biopharma Platform, from small firms to large enterprises across 21+ industries.

Organizations such as Roche, AstraZeneca, Merck, Pfizer and Bayer are recorded users of Genedata Biopharma Platform for Life Science R&D Platforms.

Companies using Genedata Biopharma Platform are most concentrated in Life Sciences, with adoption spanning over 21 industries.

Companies using Genedata Biopharma Platform are most concentrated in Switzerland, United Kingdom and United States, with adoption tracked across 195 countries worldwide. This global distribution highlights the popularity of Genedata Biopharma Platform across Americas, EMEA, and APAC.

Companies using Genedata Biopharma Platform range from small businesses with 0-100 employees - 6.25%, to mid-sized firms with 101-1,000 employees - 18.75%, large organizations with 1,001-10,000 employees - 18.75%, and global enterprises with 10,000+ employees - 56.25%.

Customers of Genedata Biopharma Platform include firms across all revenue levels — from $0-100M, to $101M-$1B, $1B-$10B, and $10B+ global corporations.

Contact APPS RUN THE WORLD to access the full verified Genedata Biopharma Platform customer database with detailed Firmographics such as industry, geography, revenue, and employee breakdowns as well as key decision makers in charge of Life Science R&D Platforms.